REGULATORY MILESTONES

Basilea Pharmaceutica AG (SIX:BSLN) was up CHF0.35 to CHF97.90 last week after submitting an MAA to EMA for isavuconazole to treat invasive aspergillosis and invasive mucormycosis (zygomycosis). Partner Astellas Pharma Inc. (Tokyo:4503) submitted an NDA to FDA for the product earlier this month.